News Releases

Keyword Search

Sep-17-2019
Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting
Sep-09-2019
Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer
Aug-28-2019
Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing
Aug-08-2019
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug-06-2019
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
Aug-01-2019
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
Jun-10-2019
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
Jun-03-2019
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib
May-15-2019
Oncternal to Present Interim Phase 1/2 Cirmtuzumab Data at ASCO
Mar-07-2019
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies